arrow
M

Martin Eklund

karolinska institutet
H指数:47
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative analysis of end-to-end learning and foundation models for clinical-grade prostate pathology

临床级前列腺病理中端到端学习与基础模型的比较分析

2026-10-260
OAAI
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design

WISDOM随机试验比较基于风险与年度乳腺癌筛查:研究队列特征与设计

2026-05-240
OAAI
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study

在美国使用快速前瞻性分类(SPARC)识别严重急性低氧性呼吸衰竭和急性呼吸窘迫综合征中的生物亚表型:一项多中心、观察性研究

2026-05-150
PRE
BIOCHEMICAL RECURRENCE DEFINITIONS TO COMPARE LONG-TERM PROSTATE CANCER MORTALITY AFTER RADIOTHERAPY OR RADICAL PROSTATECTOMY

生化复发定义的比较:放疗或根治性前列腺切除术后的长期前列腺癌死亡率

2026-05-010
PRE
IS THE DIGITAL RECTAL EXAM (DRE) STILL RELEVANT IN THE ERA OF MRI IMAGING? RESULTS OF AN INTERNATIONAL MULTI-INSTITUTIONAL STUDY

数字直肠检查(DRE)在MRI成像时代是否仍然相关?国际多机构研究的结果

2026-05-010
PRE
Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

作者更正:系统化数据采集减少了对源数据核查的需求:一项来自第2阶段多中心随机对照平台试验的探索性分析

2026-03-240
OAAI
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

系统化数据捕获减少了源数据验证的需求:一项来自一项多中心随机对照平台试验的探索性分析

2025-10-290
OAAI
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Stockholm3 与前列腺特异性抗原在前列腺癌筛查中的比较:来自 STHLM3 试验的 9 年随访结果,表明提高了侵袭性癌的检出率并减少了过度诊断

2025-10-160
OAAI
The Effects of Cyproheptadine on Severe COVID-19 From the I-SPY COVID Adaptive Platform Trial

Cyproheptadine对重症COVID-19的影响:来自I-SPY COVID适应性平台试验

2025-10-010
OAAI
Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial

在WISDOM研究中大规模整合乳腺癌多基因风险评分:一项全国性随机个性化筛查试验

2025-08-300
OAAI
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer

放射治疗后可检测到的前列腺特异性抗原,用于临床局限性前列腺癌

Cancer
IF5.1
2025-08-170
OAAI
Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial

前列腺特异性抗原密度作为磁共振成像前前列腺癌筛查的筛选工具:来自STHLM3MRI随机临床试验的分析

2025-07-290
OAAI
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment

高危生化复发在前列腺癌初次治疗后的流行病学

2025-06-010
OAAI
Physical Color Calibration of Digital Pathology Scanners for Robust Artificial Intelligence-Assisted Cancer Diagnosis

数字病理扫描仪的物理颜色校准,用于稳健的人工智能辅助癌症诊断

2025-05-010
OAAI